Skip to content

Clinical intervention of Shen-Qi Paste on end-stage renal disease with sarcopenia

Clinical intervention of Shen-Qi Paste on end-stage renal disease with sarcopenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000438
Enrollment
Unknown
Registered
2025-02-27
Start date
2024-04-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Experimental Group:Shenqi Paste + exercise
Control group:Shenqi ointment control + exercise

Sponsors

Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) The diagnosis met the western medical diagnostic criteria of end-stage renal disease GFR3 months; 3) age of 45 to 75 years old (according to the age distribution of dialysis patients); 4) voluntary participation in this study and signed informed consent. According to the diagnosis of sarcopenia the patients with sarcopenia and willing to participate in the clinical trial should also meet the following conditions: (5) patients with spleen and kidney deficiency diagnosed by TCM syndrome differentiation;

Exclusion criteria

Exclusion criteria: 1) Bioelectrical impedance is contraindicated in the implantation of metal devices or electronic medical devices such as pacemakers; (2) pregnant or lactating women; 3) patients with severe abnormalities of heart liver and hematopoietic system; 4) Inability to cooperate with patients with mental and emotional disorders (schizophrenia depression anxiety etc.). According to the diagnosis of sarcopenia patients with sarcopenia who were willing to participate in the clinical trial were also required to meet the following conditions: (5) patients with malignant tumor severe infection severe gastrointestinal bleeding active tuberculosis and other diseases affecting nutritional status; 6) physical disability unwillingness to participate in the study or inability to complete the follow-up; 7) Patients with poor compliance to treatment; 8) Patients who are participating in other clinical trials or taking traditional Chinese medicine.

Design outcomes

Primary

MeasureTime frame
Five Times Sit-to-Stand Test;Grip strength;Muscle mass /SMI index;

Secondary

MeasureTime frame
C-reactive protein;Frailty Scale (FRAIL);Short Form Health Survey (SF-36);TCM syndrome score and efficacy criteria;Pittsburgh Sleep Quality Index (PSQI) scale was used;Myostatin/MSTN;Mini nutritional assessment-short form (MNA-SF) ;TNF-a;Activities of Daily Living (ADL);Irisin;Self-rating Depression Scale (SDS);

Countries

China

Contacts

Public ContactQiuhua Sun

Zhejiang Chinese Medical University

sqh80701@163.com13906539898

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026